Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering announced on November 09th the expansion of its portfolio of RNA based bioplatform companies with the unveiling of Alltrna, the first transfer RNA (tRNA) platform company to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Flagship's initial commitment to Alltrna is $50 million. Alltrna's platform combines internal expertise and proprietary machine learning tools to unlock the ...
Read More
Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu announced on November 22nd that it has entered Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines. Baidu, a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline. Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses. This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize ...
Read More
Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

On November 18th the Copenhagen-based pharma giant put out word that it is buying Dicerna $DRNA — an RNAi pioneer that has had its up and downs over the years — for $3.3 billion. Novo is paying $38.25 a share — an 80% premium. That first effort in their alliance was targeted at cardiometabolics, a top priority now as Novo moves past their big R&D campaign for semaglutide and looks to put new drugs in the pipeline. The collaboration overall was exploring more than 30 liver cell targets “with the potential to deliver multiple clinical candidates for disorders including chronic ...
Read More
Moderna founder unveils new drug company focused on a different kind of RNA

Moderna founder unveils new drug company focused on a different kind of RNA

At the tail end of this operation are transfer RNAs, which, as the name suggests, carry and ultimately hand off the correct building blocks — known as amino acids — to the ribosome. But despite their crucial role, these molecules haven't attracted as much attention as other types of RNA. An article published not too long ago in the journal Cell Research claimed tRNA is "generally not on the mind of most research scientists, unless they meet it through chance encounter." Now named Alltrna, the company officially launched on November 09th with an initial commitment of $50 million from Flagship. The firm's ...
Read More
Best Sites to Download Wii U ROMs For Cemu

Best Sites to Download Wii U ROMs For Cemu

We are glad to announce about the best sites to download the Wii U ROMs for Cemu have been introduced on techspunk.com. The users can find the list of the most demanding Wii U ROMs for Cemu, along with the details and their download links. We have mentioned the particular options available on these sites which assist you in downloading game ROMs. The great lines for Wii U ROMs… If you would like to play the Wii games and searching for the emulators, then read the complete blog to collect the details and choose any of them. I did a ...
Read More
Gritstone Poised To Dominate mRNA Market

Gritstone Poised To Dominate mRNA Market

Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock.Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Redmile Group, and Gilead Sciences.Gritstone announced groundbreaking early-stage clinical data at ESMO 2021 from their personalized immunotherapy program GRANITE for microsatellite stable colorectal cancer; pivotal trial to start soon.The company has multiple ongoing trials that are evaluating self-amplifying mRNA as next-gen vaccine technology to combat COVID-19.GRTS recently dosed the first solid tumor patient in Phase 2 clinical ...
Read More
Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

SPH SINE, a subsidiary of China's Shanghai Pharma, acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and  KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for China trials and commercialization. For further information, see Chinabio Today (http://www.chinabiotoday.com/articles/shanghai-pharma-microbiome-110-million) Creative abstract social print ...
Read More

Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering announced on November 09th the expansion of its portfolio of RNA based bioplatform companies with the unveiling of Alltrna, the first transfer RNA (tRNA) platform company to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Flagship's initial commitment to Alltrna is $50 million. Alltrna's platform combines internal expertise and proprietary machine learning tools to unlock the ...
Read More
Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu announced on November 22nd that it has entered Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines. Baidu, a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline. Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses. This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize ...
Read More
Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

On November 18th the Copenhagen-based pharma giant put out word that it is buying Dicerna $DRNA — an RNAi pioneer that has had its up and downs over the years — for $3.3 billion. Novo is paying $38.25 a share — an 80% premium. That first effort in their alliance was targeted at cardiometabolics, a top priority now as Novo moves past their big R&D campaign for semaglutide and looks to put new drugs in the pipeline. The collaboration overall was exploring more than 30 liver cell targets “with the potential to deliver multiple clinical candidates for disorders including chronic ...
Read More
Moderna founder unveils new drug company focused on a different kind of RNA

Moderna founder unveils new drug company focused on a different kind of RNA

At the tail end of this operation are transfer RNAs, which, as the name suggests, carry and ultimately hand off the correct building blocks — known as amino acids — to the ribosome. But despite their crucial role, these molecules haven't attracted as much attention as other types of RNA. An article published not too long ago in the journal Cell Research claimed tRNA is "generally not on the mind of most research scientists, unless they meet it through chance encounter." Now named Alltrna, the company officially launched on November 09th with an initial commitment of $50 million from Flagship. The firm's ...
Read More
Best Sites to Download Wii U ROMs For Cemu

Best Sites to Download Wii U ROMs For Cemu

We are glad to announce about the best sites to download the Wii U ROMs for Cemu have been introduced on techspunk.com. The users can find the list of the most demanding Wii U ROMs for Cemu, along with the details and their download links. We have mentioned the particular options available on these sites which assist you in downloading game ROMs. The great lines for Wii U ROMs… If you would like to play the Wii games and searching for the emulators, then read the complete blog to collect the details and choose any of them. I did a ...
Read More
Gritstone Poised To Dominate mRNA Market

Gritstone Poised To Dominate mRNA Market

Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock.Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Redmile Group, and Gilead Sciences.Gritstone announced groundbreaking early-stage clinical data at ESMO 2021 from their personalized immunotherapy program GRANITE for microsatellite stable colorectal cancer; pivotal trial to start soon.The company has multiple ongoing trials that are evaluating self-amplifying mRNA as next-gen vaccine technology to combat COVID-19.GRTS recently dosed the first solid tumor patient in Phase 2 clinical ...
Read More
Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

SPH SINE, a subsidiary of China's Shanghai Pharma, acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and  KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for China trials and commercialization. For further information, see Chinabio Today (http://www.chinabiotoday.com/articles/shanghai-pharma-microbiome-110-million) Creative abstract social print ...
Read More
Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine

Flagship Pioneering announced on November 09th the expansion of its portfolio of RNA based bioplatform companies with the unveiling of Alltrna, the first transfer RNA (tRNA) platform company to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Flagship's initial commitment to Alltrna is $50 million. Alltrna's platform combines internal expertise and proprietary machine learning tools to unlock the ...
Read More
Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

Baidu announced on November 22nd that it has entered Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines. Baidu, a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline. Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses. This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize ...
Read More
Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

On November 18th the Copenhagen-based pharma giant put out word that it is buying Dicerna $DRNA — an RNAi pioneer that has had its up and downs over the years — for $3.3 billion. Novo is paying $38.25 a share — an 80% premium. That first effort in their alliance was targeted at cardiometabolics, a top priority now as Novo moves past their big R&D campaign for semaglutide and looks to put new drugs in the pipeline. The collaboration overall was exploring more than 30 liver cell targets “with the potential to deliver multiple clinical candidates for disorders including chronic ...
Read More
Moderna founder unveils new drug company focused on a different kind of RNA

Moderna founder unveils new drug company focused on a different kind of RNA

At the tail end of this operation are transfer RNAs, which, as the name suggests, carry and ultimately hand off the correct building blocks — known as amino acids — to the ribosome. But despite their crucial role, these molecules haven't attracted as much attention as other types of RNA. An article published not too long ago in the journal Cell Research claimed tRNA is "generally not on the mind of most research scientists, unless they meet it through chance encounter." Now named Alltrna, the company officially launched on November 09th with an initial commitment of $50 million from Flagship. The firm's ...
Read More
Best Sites to Download Wii U ROMs For Cemu

Best Sites to Download Wii U ROMs For Cemu

We are glad to announce about the best sites to download the Wii U ROMs for Cemu have been introduced on techspunk.com. The users can find the list of the most demanding Wii U ROMs for Cemu, along with the details and their download links. We have mentioned the particular options available on these sites which assist you in downloading game ROMs. The great lines for Wii U ROMs… If you would like to play the Wii games and searching for the emulators, then read the complete blog to collect the details and choose any of them. I did a ...
Read More
Gritstone Poised To Dominate mRNA Market

Gritstone Poised To Dominate mRNA Market

Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock.Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Redmile Group, and Gilead Sciences.Gritstone announced groundbreaking early-stage clinical data at ESMO 2021 from their personalized immunotherapy program GRANITE for microsatellite stable colorectal cancer; pivotal trial to start soon.The company has multiple ongoing trials that are evaluating self-amplifying mRNA as next-gen vaccine technology to combat COVID-19.GRTS recently dosed the first solid tumor patient in Phase 2 clinical ...
Read More
Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

SPH SINE, a subsidiary of China's Shanghai Pharma, acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and  KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for China trials and commercialization. For further information, see Chinabio Today (http://www.chinabiotoday.com/articles/shanghai-pharma-microbiome-110-million) Creative abstract social print ...
Read More